Lv2
190 积分 2024-04-07 加入
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
6天前
已完结
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study
12天前
已完结
Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and association with outcomes to immunotherapy +/- chemotherapy in nonsquamous non-small cell lung cancer
18天前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
20天前
已完结
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
2个月前
已完结
[Clinical pathological features and progress of Fumarate hydratase-deficient renal cell carcinoma]
2个月前
已完结
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
3个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
4个月前
已完结
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
5个月前
已完结
[Consensus on clinical diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma]
5个月前
已完结
皖公网安备34019202002308
